Expertise in
1
conditions

Helene Monjanel

Aurillac, FR 
Expertise in
1
conditions
Aurillac, FR 

Overview

Helene Monjanel practices practicing medicine in Aurillac, France.

Ms. Monjanel is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Follicular Lymphoma, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 19 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Aurillac, France
Other Locations
CHU de Reims
Reims, France
Vichy, France
Clermont-ferrand, France
Tours, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Drugs: Lenalidomide, Rituximab
Study Phase: Phase 3
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Enrollment Status: Completed
Publish Date: July 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

19 Total Publications

Large B-cell lymphoma: The LYSA pragmatic guidelines.
Large B-cell lymphoma: The LYSA pragmatic guidelines.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 21, 2025

Frequently Asked Questions about Helene Monjanel

Is Helene Monjanel a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Helene Monjanel is classified as an Advanced expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Helene Monjanel participate in research or clinical trials?

Yes. Helene Monjanel has published 19 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Helene Monjanel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Monjanel's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile